- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02748551
A Comparison Laparoscopic With Open Gastric Cancer Surgery for Locally Advanced Gastric Cancer
Prospective Multicenter Study on Laparoscopic Gastric Cancer Surgery Compared With Open Surgery for Locally Advanced Gastric Cancer
Nowadays, the proportion of patients with locally advanced gastric cancer is estimated up to 90 percent of all gastric cancer cases in Russian Federation. Surgical procedure with D2 Lymphadenectomy is the main option for treatment. Conventional open approach is still the current standard for advanced gastric cancer. Laparoscopic procedures for gastric cancer as minimally invasive surgery has gained popularity for the treatment of early gastric cancer in East Asia. Several studies indicated that laparoscopic procedures both total and subtotal gastrectomy with D2 lymphadenectomy is a technically feasible and safe procedure by experienced surgeons in high-volume specialized hospitals. However, lack of solid evidence on the oncologic efficacy.
Starting clinical trials for evaluate safety of oncology laparoscopic subtotal gastrectomy for locally advanced gastric cancer. Aim of this trial is show safety, feasibility and oncologic efficacy of Laparoscopic radical surgical procedures both total and subtotal gastrectomy for treatment gastric cancer.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Verwacht)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Igor Khathov, MD, PhD
- Telefoonnummer: 8 (495) 3042908
- E-mail: ihatkov@gmail.com
Studie Contact Back-up
- Naam: Roman Izrailov, MD, PhD
- Telefoonnummer: 8 (495) 3042908
- E-mail: izrailev@mail.ru
Studie Locaties
-
-
-
Kiev, Oekraïne
- Werving
- Lisod clinic
-
Contact:
- Sergey Baydo, MD, PhD
-
-
-
-
-
Lipetsk, Russische Federatie
- Werving
- Lipetsk regional oncological center
-
Contact:
- Michail Lando, MD, PhD
- E-mail: abdlan@yandex.ru
-
Moscow, Russische Federatie, 111123
- Werving
- Moscow Clinical Scientific Center
-
Contact:
- Roman Izrailov, MD, PhD
- Telefoonnummer: 8 (495) 3042908
- E-mail: izrailev@mail.ru
-
Contact:
- Boris Pomortsev, MD
- Telefoonnummer: 8(915)2107630
- E-mail: b.pomortsev@mknc.ru
-
Onderonderzoeker:
- Michail Prostov
-
Moscow, Russische Federatie
- Werving
- Moscow Oncology Hospital 62
-
Contact:
- Pavel Kononets
- E-mail: p.kononets@onco62.ru
-
Moscow, Russische Federatie
- Werving
- P.Herzen Moscow Oncological Research Institute
-
Contact:
- Andrey Ryabov, MD, PhD
- E-mail: ryabovdoc@mail.ru
-
Moscow, Russische Federatie
- Werving
- Treatment and Rehabilitation Centre of Health Ministry of Russia
-
Contact:
- Vladimir Lyadov, MD, PhD
- E-mail: vlyadov@gmail.com
-
St. Petersburg, Russische Federatie
- Werving
- Leningradsky oncological center
-
Contact:
- Andrey Pavlenko, MD, PhD
- E-mail: andrewpavlenko@yandex.ru
-
St.Petersburg, Russische Federatie
- Werving
- Federal Medical Biology Agence №122 the name of L.Soko
-
Contact:
- Victor Kashchenko, MD, PhD
- E-mail: med@fromru.com
-
St.Petersburg, Russische Federatie
- Werving
- N. Petrov National Research Institute of Oncology
-
Contact:
- Alexey Karachun, MD, PhD
- E-mail: dr.a.karachun@gmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- ECOG 0-1
- ASA I-III
- Histologically proven cancer of the stomach cT 2-4a(clinical stage tumor), N0-3, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Seventh Edition
- Preoperative examination with no distant metastasis, no significantly enlarged lymph nodes around abdominal main artery, and tumor not a direct violation of the pancreas, spleen and other surrounding organs
- The gastric tumors are located in the stomach, are macroscopically resectable by subtotal or total gastrectomy with D2 lymph node dissection.
- Written informed consent
Exclusion Criteria:
- Clinically apparent distant metastasis
- Free cancer cells
- Bulky lymph node metastasis is detected by abdominal CT
- Previous treatment with radiation therapy for any tumors.
- Previous surgery for the present disease
- Pregnancy
- Psychiatric disease
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Laparoscopic surgery
Traditional open procedure for patient with locally advanced gastric cancer
|
Open surgery
|
Actieve vergelijker: Open surgery
Minimum invasive procedure (laparoscopic) for patient with locally advanced gastric cancer
|
Laparoscopic surgery
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
"Major" Surgical Morbidity
Tijdsspanne: 21 days.
|
"Major" Surgical morbidity is defined as the complication grade on III-V Clavien-Dindo Classification which occurs with-in postoperative 21 days, extension of hospitalization and re-hospitalization.
It is necessary to evaluate the complication and if it occurs during the hospitalization, it is required to record complication name, date of on-set (postoperatively), grade on Clavien-Dindo Classification and treatment for complication.
|
21 days.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
3-year progression-free survival
Tijdsspanne: 36 months
|
In terms of locally advanced gastric cancer, to evaluate the progression-free survival rate in laparoscopic gastrectomy with D2 lymph node dissection at postoperative 3 years compared with open procedures
|
36 months
|
3-year overall survival
Tijdsspanne: 6, 12, 18, 24, 30 and 36 months
|
In terms of locally advanced gastric cancer, to evaluate the overall survival rate in laparoscopic gastrectomy with D2 lymph node dissection at postoperative 3 years compared with open procedures
|
6, 12, 18, 24, 30 and 36 months
|
5-year overall survival rate
Tijdsspanne: 6, 12, 18, 24, 30, 36, 48 and 60 months
|
In terms of locally advanced gastric cancer, to evaluate the overall survival rate in laparoscopic gastrectomy with D2 lymph node dissection at postoperative 5 years compared with open procedures
|
6, 12, 18, 24, 30, 36, 48 and 60 months
|
Surgical Mortality
Tijdsspanne: 90 days
|
It is defined as the death within postoperative 90 days regardless of postoperative reason.
|
90 days
|
Peri-operative blood loss
Tijdsspanne: 1 day
|
Minimally-invasive surgery is associated with less peri-operative blood loss.
Blood loss will be measured in milliliters and average blood loss will be compared to the conventional 'open' group.
|
1 day
|
Postoperative recovery index
Tijdsspanne: 10 days
|
Time to first ambulation, flatus, liquid diet, soft diet, and duration of hospital stay are used to assess the postoperative recovery course The amount of abdominal drainage and blood transfusion are also recorded
|
10 days
|
Pain scores
Tijdsspanne: up to 3 days after surgery
|
Pain scores based on a visual analog scale the day of surgery and the subsequent 3 days postoperative 1 days, 2 days, 3 days
|
up to 3 days after surgery
|
Postoperative quality of life
Tijdsspanne: 6, 12, 18, 24, 30 and 36 months
|
Both the European Organization for Research and Treatment of Cancer (EORTC) C30 and STO22 are analyzed with quality of life
|
6, 12, 18, 24, 30 and 36 months
|
long-term surgical morbidity
Tijdsspanne: 21days - 36 months after surgery
|
Surgical morbidity is defined as the events which occurs with-in postoperative 21 days - 36 months after surgery.
It is necessary to evaluate the complication, it is required to record complication name, date of on-set.
Long complications are included: hernia, bleeding, bowel obstruction etc.
|
21days - 36 months after surgery
|
Extent of lymph node dissection
Tijdsspanne: 2 weeks
|
The extent of lymph node dissection in treatment of gastric cancer is considered a prognostic marker for postoperative survival and disease-free survival.
Before implementation of a new surgical technique, it is imperative that this technique is non-inferior with regard to the extent of lymph node dissection.
Measures will include the number of resected lymph nodes and the number of resected lymph node stations.
|
2 weeks
|
Medewerkers en onderzoekers
Onderzoekers
- Studie stoel: Michail Byachov, MD, PhD, Moscow Clinical Scientific Center
- Studie stoel: Roman Izrailov, MD, PhD, Moscow Clinical Scientific Center
- Hoofdonderzoeker: Boris Pomortsev, MD, Moscow Clinical Scientific Center
- Hoofdonderzoeker: Pavel Kononets, MD, PhD, Moscow Oncological Hospital 62
- Hoofdonderzoeker: Andrey Ryabov, MD, PhD, P.Herzen Moscow Oncological Research Institute
- Hoofdonderzoeker: Vladimir Lyadov, MD, PhD, Treatment and Rehabilitation Centre of Health Ministry of Russia
- Hoofdonderzoeker: Alexey Karachun, MD, PhD, N. Petrov National Research Institute of Oncology
- Hoofdonderzoeker: Victor Kashchenko, MD, PhD, Federal Medical Biology Agence №122 the name of L.Sokolov
- Hoofdonderzoeker: Andrey Pavlenko, MD, PhD, Leningradsky oncological center
- Hoofdonderzoeker: Michail Lando, MD, PhD, Lipetsk regional oncological center
- Hoofdonderzoeker: Sergey Baydo, MD, PhD, Lisod clinic Kiev
- Studie directeur: Igor Khatkov, MD, PhD, Moscow Clinical Scientific Center
- Hoofdonderzoeker: Michail Prostov, Moscow Clinical Scientific Center
- Hoofdonderzoeker: Kirill Schostka, MD, PhD, Leningradsky oncological center
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- MKNC 01/2016
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Maagkanker
-
RSP Systems A/SVoltooid
-
Medtronic - MITGVoltooid
-
State University of New York - Upstate Medical...BeëindigdGastric Bypass-statusVerenigde Staten
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)IngetrokkenGastric Bypass-operatie
-
Olympus Corporation of the AmericasUnity Health TorontoVoltooid
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaVoltooidRoux en Y Gastric BypassVerenigde Staten
-
North Dakota State UniversityNational Institutes of Health (NIH)VoltooidRoux en Y Gastric Bypass ChirurgieVerenigde Staten
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaVoltooidSleeve gastrectomie | Roux en Y Gastric BypassVerenigde Staten
-
Medical University of South CarolinaVoltooidGastric Bypass Chirurgie PijnbestrijdingVerenigde Staten
-
Rijnstate HospitalVoltooid
Klinische onderzoeken op Open Surgery
-
University Hospital Inselspital, BerneVoltooidGerandomiseerde gecontroleerde studie | Ventriculaire peritoneale shunt | Shunt-complicaties | Shunt defectZwitserland
-
First Affiliated Hospital Xi'an Jiaotong UniversityOnbekendSpinale neoplasmataChina
-
Intuitive SurgicalActief, niet wervendColorectale kanker | Goedaardige of kwaadaardige tumoren van het rectum of de dikke darmVerenigde Staten, Korea, republiek van
-
Mayo ClinicBeëindigdGastro-oesofageale reflux | Hernia, Hiatal | Enquêtes en vragenlijsten | FundoplicatieVerenigde Staten
-
NYU Langone Health7D Surgical Inc.IngetrokkenScoliose | Wervelkanaalstenose | Spondylolisthesis
-
University of TriesteVoltooid
-
AGO Study GroupCancer Research UK; ARCAGY/ GINECO GROUP; Grupo Español de Investigación en Cáncer... en andere medewerkersVoltooidEierstokkanker | Eileiderkanker | Peritoneale holtekankerSpanje, Frankrijk, Denemarken, België, Duitsland, Oostenrijk, China, Italië, Korea, republiek van, Noorwegen, Zweden, Verenigd Koninkrijk
-
Dr. Faruk SemizAanmelden op uitnodiging
-
National Cancer Centre, SingaporeVoltooidSchildklier ZiektenSingapore
-
Hospital Universitari de BellvitgeGermans Trias i Pujol Hospital; University of BarcelonaWervingNaleving, patiënt | Naleving, behandeling | De rol van de verpleegster | Ziekte van de dikke darm | Verbeterd herstel | ERAS | Ziekte van het rectumSpanje